Sunday - June 2, 2024
Sanofi: Beyfortus Real-World Evidence Published in The Lancet Shows 82% Reduction in Infant RSV Hospitalizations
May 03, 2024
PARIS, France, May 3 (TNSres) -- Sanofi, a life sciences company, issued the following news release on May 2, 2024:

* * *

* New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6

* Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products